Unlocking Japan | Accelerating Global Drug Development from Day One

Session Focus

Okuma opened with the case for Japan as a market and the problem the panel was assembled to address.

Japan is the world’s third largest pharmaceutical market and runs on universal health insurance, which means drugs approved by the PMDA, Japan’s regulatory agency, are almost immediately reimbursed. Every patient in Japan gains access to approved drugs.

Despite that, biotechs and pharmaceutical companies from abroad routinely relegate Japan to a late-stage afterthought, which costs the industry its most valuable resource: time.

She positioned the four panelists at four different points along the same road toward fixing that. National Cancer Center Japan operates a government-funded initiative building an on-ramp for foreign companies. Takeda has been on the road for decades. Orion has just merged onto it. Strand is looking for the entrance.

The stated goal was a concrete day one checklist by the end of the session.

What a National On-Ramp Provides

Wakako Toga PhD described Ensemble CrossJ as a national initiative funded by the Japanese government, led by the National Cancer Center in collaboration with five other national centers, covering all disease areas despite the cancer center’s leadership.

The mission is helping global biotech companies engage effectively with Japanese healthcare and its innovation ecosystem.

Her diagnosis of the problem was specific. Many biotechs want to explore opportunities in Japan but do not know where or how to start. They lack visibility into the updated ecosystem, the right partners, and the clinical and scientific capabilities available.

The deeper issue she identified is less obvious and more important. Companies are unsure how to incorporate Japan into a global strategy at all, because they assume Japan is separate and different and must be planned for separately.

What the initiative provides runs in sequence. It convenes expertise across academia, industry and government to clarify what advantages Japan offers and how to involve it in a global strategy. It helps construct scenarios that maximize business and regulatory incentives. And it supports the company in reaching a go or no-go decision.

She was notably direct that the initiative supports a no-go decision as readily as a go, since the decision belongs to the company.

Her worked example of an advantage companies may not know about: patent term extension. Japan’s patent term is roughly twenty years, matching global expiration. But the patent clock can be stopped during clinical trials used for Japanese submission, for up to five years, which can then be added to the original term. That produces up to twenty five years of exclusivity in Japan.

Once a strategy is fixed, the initiative introduces companies to appropriate partners, whether CROs for development or pharmaceutical partners for post-launch business expansion, through a partnering consortium.

What Changes When Japan Is Not a Separate Market

Liz Lewis addressed the structural question from inside a company where Japan is home and R&D headquarters sit in Cambridge.

She anticipated the obvious question about why a pricing and access person sits on a development panel, and answered it directly: access considerations determine how quickly innovative medicines reach the patients who need them, which makes them a development concern.

Her critique of the conventional approach was precise. A bridging study addressing Japan after US and European approval sounds like a fast track. You get approval quickly in the US and Europe, then work out what Japan requires.

The alternative changes what questions get asked and when. Treating Japan as integral to the development plan means asking early what data is needed to optimize bringing the drug to Japanese patients, accounting for the pathways available including orphan drug designation and Sakigake, and for mechanisms such as foreign price adjustment that add value to the medicine globally.

Her summary of the benefit: it allows a company to be genuinely proactive rather than reactive, even where not all answers are available at the outset.

Key Takeaways

1. Japan is the third largest pharmaceutical market with universal insurance, so PMDA approval means near-immediate reimbursement.

2. Treating Japan as a late-stage afterthought costs time, the industry’s most valuable resource.

3. The barrier is often not willingness but knowledge of how to incorporate Japan into a global rather than separate strategy.

4. A government-funded initiative now provides that on-ramp across all disease areas, and supports no-go decisions as readily as go.

5. Patent term extension can stop the clock during Japanese trials, producing up to 25 years of exclusivity.

6. Bridging studies after US and EU approval look fast but forgo the regulatory pathways and pricing mechanisms available to early planners.